GLP3 / R

Price range: $35.00 through $475.00

Pure GLP3 / Reta vials and vial kits.  Free Same Day FedEx 2-day shipping on all orders over $50.

SKU: N/A Category: Tags: , , ,

Description

  GLP3 / Reta

  •  Supplied as a lyophilized powder vial, manufactured to the highest chemical standards. Every batch is strictly synthesized as a reference standard for laboratory evaluation, in-vitro testing, and scientific development purposes. 

  •  Each size variation is accompanied by an independent third-party Certificate of Analysis (COA) verifying a purity level of 99% or higher, ID, net vial content, endotoxins, and vial conformity.

  • https://aminoshoppe.com/lab-tests/
  •  Laboratory Research Notice: This product is intended strictly for laboratory research and development use only.

Retatrutide
Clinical data
Other names LY-3437943
Identifiers
CAS Number
UNII
ChEMBL
Chemical and physical data

GLP3 / R is a peptide with the following amino acid sequence:YA¹QGTFTSDYSIL²LDKK⁴AQA¹AFIEYLLEGGPSSGAPPPS³where letters with superscripted numbers refer to the following chemical modifications:

  • A¹ –2-aminoisobuttyric acid

  • L² – leucine modified with an α-methyl substituent (MeL, 2-methylleucine).

  • S³ – L-serinamide (L-serine with the carboxylic acid group replaced with carboxomide).

  • K⁴ – L-lysine with the amino group at position 6 modified with a side chain; specifically, (AEEA)-(γ-Glu)-(C20 diacid) (where AEEA is 2-[2-(2-aminoethoxy)ethoxy]acetic acid, commonly used as a spacer group in synthetic peptides).

GLP3 / R is synthetically engineered and produced using solid-phase peptide synthesis (SPPS). This is when amino acids are added to a peptide chain and attached to solid resin forming a backbone. After the backbone is synthesized, the molecule is cleaved chemically, then purified. Lipidation modifications also occur, meaning a fatty-acid side chain is added to promote reversible binding to albumin. This modification allows for a longer drug half-life..

HALF-LIFE: WHAT CLINICAL DATA SHOWS

Early pharmacokinetic studies suggest that Retatrutide has a half-life of approximately 6–8 days, placing it in the same range as other long-acting incretin-based peptides.

COMPARISON TO OTHER GLP-1/GIP THERAPIES

→ GLP-1 : Half-life ~7 days
→ GLP-2: Half-life ~5 days
→ GLP-3: Half-life ~6–8 days

Additional information

Strength

1 vial-5mg, 1 vial-10mg, 1 vial-20mg, 1 vial-30mg, 5 vials-10mg, 10 vials-10mg, 5 vial-30mg